Treatment of cornea using laminin
AssigneesKyoto Prefectural Public University Corporation, The Doshisha, Senju Pharmaceutical Co., Ltd.
InventorsNoriko Koizumi, Naoki Okumura, Shigeru Kinoshita
Life of this patent
Estimating the term…
Abstract
The present invention provides a technique for treating the cornea. More specifically, the present invention is an agent for the treatment or prevention of a state of corneal endothelial disease, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with corneal endothelial cells. Specifically, the present invention can include laminin 511 (α5β1γ1), laminin 521 (α5β2γ1), or a fragment of these.
Claims15
A method for treating a disease, a disorder, or a condition of a corneal endothelium of a subject, comprising administering a corneal endothelial cell suspension comprising a therapeutically effective amount of at least one agent selected from the group consisting of laminins and fragments thereof to the subject, wherein the laminins and fragments thereof comprise an α5 chain and/or a y1 chain.
Dependencies are inferred from the claim text.